MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver ...
Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback